CoChat
Sign Up
Cited by 63

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives

Ansari, Mohammad Azam, Thiruvengadam, Muthu, Venkidasamy, Baskar, Alomary, Mohammad N., Salawi, Ahmad, Chung, Ill-Min, Shariati, Mohammad Ali, Rebezov, Maksim·2022·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2022.04.005
Open this paper in CoChat — free account

Abstract

Cancer is one of the dreadful diseases worldwide. Surgery, radiation and chemotherapy, are the three basic standard modes of cancer treatment. However, difficulties in cancer treatment are increasing due to immune escape, spreading of cancer to other places, and resistance of cancer cells to therapies. Various signaling mechanisms, including PI3K/Akt/mTOR, RAS, WNT/β-catenin, TGF-beta, and notch pathways, are involved in cancer resistance. The adaptive inflammatory response is the initial line of defence against infection. However, chronic inflammation can lead to tumorigenesis, malignant transformation, tumor growth, invasion, and metastasis. The most commonly dysregulated inflammatory pathways linked to cancer include NF-κB, MAPK, JAK-STAT, and PI3K/AKT. To overcome major hurdles in cancer therapy, nanomedicine is receiving much attention due to its role as a vehicle for delivering chemotherapeutic agents that specifically target tumor sites. Several biocompatible nanocarriers including polymer and inorganic nanoparticles, liposomes, micellar nanoparticles, nanotubes, and exosomes have been extensively studied. Exosome has been reported as an important potential system that could be effectively used as a bioinspired, bioengineered, and biomimetic drug delivery solution considering its toxicity, immunogenicity, and rapid clearance by the mononuclear phagocyte system. Exosome-mimetic vesicles are receiving much interest for developing nano-sized delivery systems. In this revi…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2022.04.005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 201

  1. Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer J. Clin., 71, 209
  2. Yagawa, 2017, Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery, J. Cancer Metas. Treat., 3, 218, 10.20517/2394-4722.2017.35 · DOI
  3. Zhang, 2019, Artificial chimeric exosomes for anti-phagocytosis and targeted cancer therapy, Chem. Sci., 10, 1555, 10.1039/C8SC03224F · DOI
  4. Chinen, 2015, Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence, Chem. Rev., 115, 10530, 10.1021/acs.chemrev.5b00321 · DOI
  5. Dong, 2021, Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer, Front. Pharmacol., 12, 143, 10.3389/fphar.2021.628690 · DOI
  6. Vaidyanathan, 2016, ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells, Br. J. Cancer, 115, 431, 10.1038/bjc.2016.203 · DOI · Paper page
  7. Coelho, 2017, J. Downward, oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA, Immunity, 47, 1083, 10.1016/j.immuni.2017.11.016 · DOI · Paper page
  8. Tang, 2018, Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp & Clin, Cancer Res., 37, 1
  9. Ediriwickrema, 2015, Nanotherapy for cancer: targeting and multifunctionality in the future of cancer therapies, ACS Biomater. Sci. Eng., 1, 64, 10.1021/ab500084g · DOI
  10. Zhang, 2019, A multifunctional nanotherapy for targeted treatment of colon cancer by simultaneously regulating tumor microenvironment, Theranostics, 9, 3732, 10.7150/thno.34377 · DOI
  11. Aalinkeel, 2016, Nanotherapy silencing the interleukin‐8 gene produces regression of prostate cancer by inhibition of angiogenesis, Immunology, 148, 387, 10.1111/imm.12618 · DOI
  12. Chauhan, 2019, Ormeloxifene nanotherapy for cervical cancer treatment, Int. J. Nanomed., 14, 7107, 10.2147/IJN.S200944 · DOI
  13. Kim, 2016, KIF3A binds to β-arrestin for suppressing Wnt/β-catenin signalling independently of primary cilia in lung cancer, Sci. Rep., 6, 1
  14. Elsharkasy, 2020, Extracellular vesicles as drug delivery systems: why and how?, Adv. Drug Deliv. Rev., 159, 332, 10.1016/j.addr.2020.04.004 · DOI
  15. Bulbake, 2017, Pharmaceutics, 9, 10.3390/pharmaceutics9020012 · DOI
  16. Jang, 2014, Could bioengineered exosome-mimetic nanovesicles be an efficient strategy for the delivery of chemotherapeutics?, Nanomedicine, 9, 177, 10.2217/nnm.13.206 · DOI
  17. Huda, 2021, Potential use of exosomes as diagnostic biomarkers and in targeted drug delivery: progress in clinical and preclinical applications, ACS Biomater. Sci. Eng., 7, 2106, 10.1021/acsbiomaterials.1c00217 · DOI
  18. Zöller, 2009, Tetraspanins: push and pull in suppressing and promoting metastasis, Nat. Rev. Cancer, 9, 40, 10.1038/nrc2543 · DOI
  19. Peng, 2013, Preformed albumin corona, a protective coating for nanoparticles based drug delivery system, Biomaterial, 34, 8521, 10.1016/j.biomaterials.2013.07.102 · DOI · Paper page
  20. Sun, 2013, Exosomes are endogenous nanoparticles that can deliver biological information between cells, Adv. Drug Deliv. Rev., 65, 342, 10.1016/j.addr.2012.07.002 · DOI
  21. Bunggulawa, 2018, Recent advancements in the use of exosomes as drug delivery systems, J. Nanobiotechnol., 16, 81, 10.1186/s12951-018-0403-9 · DOI
  22. Panda, 2019, Cell signaling and cancer: a mechanistic insight into drug resistance, Mol. Biol. Rep., 46, 5645, 10.1007/s11033-019-04958-6 · DOI · Paper page
  23. Liu, 2020, ASF1B promotes cervical cancer progression through stabilization of CDK9, Cell Death Dis., 11, 1, 10.1038/s41419-020-02872-5 · DOI
  24. Rutkovsky, 2019, Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer, BMC Cancer, 19, 1, 10.1186/s12885-019-5667-4 · DOI
  25. Hung, 2016, Epidermal growth factor receptor mutation enhances expression of cadherin-5 in lung cancer cells, PLoS One, 11, 10.1371/journal.pone.0158395 · DOI
  26. Testa, 2018, Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells, Med. Sci., 6, 31
  27. Pan, 2018, MORC2, a novel oncogene, is upregulated in liver cancer and contributes to proliferation, metastasis and chemoresistance, Int. J. oncol., 53, 59
  28. He, 2017, Opa interacting protein 5 acts as an oncogene in bladder cancer, J. Cancer Res. Clin. Oncol., 143, 2221, 10.1007/s00432-017-2485-4 · DOI
  29. Li, 2019, Overexpression of Opa interacting protein 5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation, Oncol. Rep., 41, 2075
  30. Wang, 2018, Loss of tumor suppressor gene function in human cancer: an overview, Cell Physiol. Biochem., 51, 2647, 10.1159/000495956 · DOI
  31. Savage, 2015, BRCA 1, a ‘complex’protein involved in the maintenance of genomic stability, FEBS J., 282, 630, 10.1111/febs.13150 · DOI
  32. Gu, 2017, Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer, Prot. Cell, 8, 455, 10.1007/s13238-017-0393-7 · DOI
  33. Senchenko, 2010, Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer, BMC Cancer, 10, 1, 10.1186/1471-2407-10-75 · DOI
  34. Gao, 2019, Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition, Nat. Commun., 10, 1, 10.1038/s41467-019-09295-7 · DOI
  35. Song, 2017, Genome-wide CRISPR screen identifies regulators of mitogen-activated protein kinase as suppressors of liver tumors in mice, Gastroent, 152, 1161, 10.1053/j.gastro.2016.12.002 · DOI
  36. Deng, 2020, Disruption of super-enhancer-driven tumor suppressor gene RCAN1. 4 expression promotes the malignancy of breast carcinoma, Mol. Cancer, 19, 1, 10.1186/s12943-020-01236-z · DOI
  37. Afgar, 2016, MiR-339 and especially miR-766 reactivate the expression of tumor suppressor genes in colorectal cancer cell lines through DNA methyltransferase 3B gene inhibition, Cancer Biol. Ther., 17, 1126, 10.1080/15384047.2016.1235657 · DOI
  38. Ma, 2021, Zi Shen decoction inhibits growth and metastasis of lung cancer via regulating the AKT/GSK-3β/β-catenin pathway, Oxid. Med. Cell Longev., 2021, 10.1155/2021/6685282 · DOI
  39. Schettino, 2013, New molecular targets in the treatment of NSCLC, Curr. Pharm. Des., 19, 5333, 10.2174/13816128113199990343 · DOI
  40. Tian, 2019, mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy, Int. J. Mol. Sci., 20, 755, 10.3390/ijms20030755 · DOI
  41. Cheung, 2021, p38 MAPK Inhibition mitigates hypoxia-induced AR signaling in castration-resistant prostate cancer, Cancers, 13, 831, 10.3390/cancers13040831 · DOI
  42. Guo, 2020, ERK/MAPK signalling pathway and tumorigenesis, Exp. Ther. Med., 19, 1997
  43. Wang, 2016, Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway, Oncotarget, 7, 2532, 10.18632/oncotarget.6304 · DOI
  44. Yang, 2020, Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways, Biosci. Rep., 40, 10.1042/BSR20193137 · DOI
  45. Uchuya-Castillo, 2018, Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity, Oncotarget, 9, 30979, 10.18632/oncotarget.25741 · DOI
  46. Chi, 2019, miR‐516a‐3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway, J. Cell Mol. Med., 23, 6295, 10.1111/jcmm.14515 · DOI
  47. Kumar, 2019, Estrogen-dependent DLL1-mediated notch signaling promotes luminal breast cancer, Oncogene, 38, 2092, 10.1038/s41388-018-0562-z · DOI
  48. Boopathy, 2019, Role of hippo pathway-YAP/TAZ signaling in angiogenesis, Front. Cell Dev. Biol., 7, 49, 10.3389/fcell.2019.00049 · DOI
  49. Lai, 2011, Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF, Cancer Res., 71, 2728, 10.1158/0008-5472.CAN-10-2711 · DOI · Paper page
  50. Zhang, 2017, Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade, Nat. Cell Biol., 19, 362, 10.1038/ncb3496 · DOI
  51. Zhao, 2021, Inflammation and tumor progression: Signaling pathways and targeted intervention, Signal Transduct. Target Ther., 6, 1
  52. Pires, 2018, NF-kappaB: two sides of the same coin, Genes, 9, 24, 10.3390/genes9010024 · DOI
  53. Bose, 2020, Targeting the JAK/STAT signaling pathway using phytocompounds for cancer prevention and therapy, Cells, 9, 1451, 10.3390/cells9061451 · DOI
  54. Dolatabadi, 2019, JAK–STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma, Int. J. Cancer, 145, 435, 10.1002/ijc.32123 · DOI
  55. Desai, 2018, Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer, Nutr. Cancer, 70, 350, 10.1080/01635581.2018.1446091 · DOI
  56. Saad, 2019, ADAM 17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer, EMBO Mol. Med., 11, 10.15252/emmm.201809976 · DOI
  57. Liu, 2018, p38β MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice, Cell Stress, 2, 311, 10.15698/cst2018.11.163 · DOI · Paper page
  58. Bonavida, 2013, Roles each of Snail, Yin Yang 1, and RKIP in the regulation of tumor cells chemo-immuno-resistance to apoptosis, Oncol. Ther., 4
  59. Chong, 2013, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat. Med., 19, 1389, 10.1038/nm.3388 · DOI
  60. Uchibori, 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer, Nat. Commun., 8, 1, 10.1038/ncomms14768 · DOI
  61. Jia, 2016, Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors, Nature, 534, 129, 10.1038/nature17960 · DOI
  62. Peng, 2019, EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression, Mol. Cancer, 18, 1, 10.1186/s12943-019-1073-4 · DOI
  63. Passarelli, 2020, Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance, Front. Immunol., 11, 1479, 10.3389/fimmu.2020.01479 · DOI
  64. Zhang, 2018, EGFR confers radioresistance in human oropharyngeal carcinoma by activating endoplasmic reticulum stress signaling PERK‐eIF2α‐GRP94 and IRE1α‐XBP1–GRP78, Cancer Med., 7, 6234, 10.1002/cam4.1862 · DOI
  65. Horn, 2015, Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma, Exp. Opin. Ther. Targets, 19, 795, 10.1517/14728222.2015.1012157 · DOI
  66. Liu, 2019, Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370, Eur. Rev. Med. Pharm. Sci., 23, 5802
  67. Ferrari, 2022, Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC, Int. J. Mol. Sci., 23, 1665, 10.3390/ijms23031665 · DOI
  68. Park, 2016, PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma, Tumor Biol., 37, 14217, 10.1007/s13277-016-5288-3 · DOI
  69. Qiao, 2017, Endoplasmic reticulum stress pathway PERK‐eIF 2α confers radioresistance in oropharyngeal carcinoma by activating NF‐κB, Cancer Sci., 108, 1421, 10.1111/cas.13260 · DOI
  70. Yeh, 2020, The protoapigenone analog WYC0209 targets CD133+ cells: A potential adjuvant agent against cancer stem cells in urothelial cancer therapy, Toxicol. Appl. Pharmacol., 402, 10.1016/j.taap.2020.115129 · DOI
  71. Liang, 2019, The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy, Oncogenesis, 8, 1, 10.1038/s41389-019-0165-8 · DOI
  72. Flem-Karlsen, 2019, p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance, Sci. Rep., 9, 1, 10.1038/s41598-019-42303-w · DOI
  73. Zhang, 2019, LMP1–positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling, Cancer Med., 8, 6082, 10.1002/cam4.2506 · DOI
  74. Kukcinaviciute, 2018, Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116, J. Cell Biochem., 119, 5913, 10.1002/jcb.26783 · DOI
  75. Yan, 2018, HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways, J. Exp. Clin. Cancer Res., 37, 1, 10.1186/s13046-018-0925-x · DOI
  76. Kumar, 2021, Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway, Nat. commun., 12, 1, 10.1038/s41467-020-20664-5 · DOI
  77. Dickson, 2009, Development of cell-cycle inhibitors for cancer therapy, Curr. Oncol., 16, 36, 10.3747/co.v16i2.428 · DOI
  78. Arrighetti, 2019, Exosome-like nanovectors for drug delivery in cancer, Curr. Med. Chem., 26, 6132, 10.2174/0929867325666180831150259 · DOI
  79. Crous, 2020, Effective gold nanoparticle-antibody-mediated drug delivery for photodynamic therapy of lung cancer stem cells, Int. J. Mol. Sci., 21, 3742, 10.3390/ijms21113742 · DOI
  80. Ramchandani, 2019, Nanoparticle delivery of miR-708 mimetic impairs breast cancer metastasis, Mol. Cancer Ther., 18, 579, 10.1158/1535-7163.MCT-18-0702 · DOI
  81. Swanner, 2019, Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo, FASEB Bio. Adv., 1, 639, 10.1096/fba.2019-00021 · DOI
  82. Ji, 2020, Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma, Acta biomater., 111, 363, 10.1016/j.actbio.2020.04.046 · DOI
  83. Wang, 2018, Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics, ACS Nano, 12, 12380, 10.1021/acsnano.8b06399 · DOI
  84. Zhang, 2015, Doxorubicin-loaded magnetic nanoparticle clusters for chemo-photothermal treatment of the prostate cancer cell line PC3, Biochem. Biophys. Res. Commun., 466, 278, 10.1016/j.bbrc.2015.09.036 · DOI
  85. Shi, 2019, Preparation and evaluation of upconversion nanoparticles based miRNA delivery carrier in colon cancer mice model, J. Biomed. Nanotechnol., 15, 2240, 10.1166/jbn.2019.2840 · DOI
  86. Liu, 2019, Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy, ACS Appl. Mat. Interfaces, 11, 47798, 10.1021/acsami.9b19446 · DOI
  87. Xu, 2020, Highly stable semiconducting polymer nanoparticles for multi-responsive chemo/photothermal combined cancer therapy, Theranostics, 10, 5966, 10.7150/thno.43090 · DOI
  88. Wadajkar, 2013, Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles, Biomaterials, 34, 3618, 10.1016/j.biomaterials.2013.01.062 · DOI
  89. Oladimeji, 2020, Co-polymer functionalised gold nanoparticles show efficient mitochondrial targeted drug delivery in cervical carcinoma cells, J. Biomed. Nanotechnol., 16, 853, 10.1166/jbn.2020.2930 · DOI
  90. Zhu, 2020, Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer, J. Nanobiotechnol., 18, 1, 10.1186/s12951-020-00686-3 · DOI
  91. Zhang, 2014, Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells, Biomaterials, 35, 3650, 10.1016/j.biomaterials.2014.01.013 · DOI
  92. Zinger, 2019, Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors, ACS Nano, 13, 11008, 10.1021/acsnano.9b02395 · DOI
  93. Vetha, 2020, Curcuminoids encapsulated liposome nanoparticles as a blue light emitting diode induced photodynamic therapeutic system for cancer treatment, J. Photochem. Photobio. B: Biol., 205
  94. Cao, 2016, Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer, ACS Nano, 10, 7738, 10.1021/acsnano.6b03148 · DOI
  95. Dana, 2020, Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer, Colloids Surf. B Biointerfaces, 196, 10.1016/j.colsurfb.2020.111270 · DOI
  96. Chu, 2016, Melanin nanoparticles derived from a homology of medicine and food for sentinel lymph node mapping and photothermal in vivo cancer therapy, Biomaterials, 91, 182, 10.1016/j.biomaterials.2016.03.018 · DOI
  97. Zhang, 2020, Hypoxia-responsive polypeptide nanoparticles loaded with doxorubicin for breast cancer therapy, ACS Biomater. Sci. Eng., 6, 2167, 10.1021/acsbiomaterials.0c00125 · DOI
  98. Joshi, 2020, Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells, Int. J. Pharm., 590, 10.1016/j.ijpharm.2020.119915 · DOI
  99. Xiao, 2012, “OA02″ peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo, Cancer Res., 72, 2100, 10.1158/0008-5472.CAN-11-3883 · DOI
  100. Lee, 2011, Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles, Mol. BioSyst., 7, 1512, 10.1039/c0mb00266f · DOI
  101. Alban, 2020, New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer, Mater. Sci. Eng: C., 110, 10.1016/j.msec.2020.110662 · DOI
  102. Safavipour, 2020, TiO2 nanotubes/reduced GO nanoparticles for sensitive detection of breast cancer cells and photothermal performance, Talanta, 208, 10.1016/j.talanta.2019.120369 · DOI
  103. Singh, 2017, Chitosan-folate decorated carbon nanotubes for site specific lung cancer delivery, Mater. Sci. Eng: C., 77, 446, 10.1016/j.msec.2017.03.225 · DOI
  104. Liu, 2019, Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes, Sci. Adv., 5, eaaw6499, 10.1126/sciadv.aaw6499 · DOI
  105. Lin, 2015, Photothermal ablation of bone metastasis of breast cancer using PEGylated multi-walled carbon nanotubes, Sci. Rep., 5, 1
  106. Yong, 2019, Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy, Nat. Commun., 10, 1, 10.1038/s41467-019-11718-4 · DOI · Paper page
  107. Bai, 2020, The role of exosomes in the female reproductive system and breast cancers, Oncol. Targets Ther., 13, 12567, 10.2147/OTT.S281909 · DOI
  108. Konoshenko, 2018, Isolation of extracellular vesicles: general methodologies and latest trends, BioMed. Res. Int., 8545347
  109. Kowal, 2014, Biogenesis and secretion of exosomes, Curr. Opin. Cell Biol., 29, 116, 10.1016/j.ceb.2014.05.004 · DOI · Paper page
  110. Sharma, 2017, Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity, Nanomedical, 12, 2137, 10.2217/nnm-2017-0184 · DOI
  111. Naseri, 2018, Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo, Int. J. Nanomed., 13, 7727, 10.2147/IJN.S182384 · DOI
  112. Gomari, 2019, Targeted delivery of doxorubicin to HER2 positive tumor models, Int. J. Nanomed., 14, 5679, 10.2147/IJN.S210731 · DOI · Paper page
  113. Hadla, 2016, Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models, Nanomedical, 11, 2431, 10.2217/nnm-2016-0154 · DOI
  114. Cheng, 2018, Reprogramming exosomes as nanoscale controllers of cellular immunity, J. Am. Chem. Soc., 140, 16413, 10.1021/jacs.8b10047 · DOI
  115. Ghavami, 2021, Radiolabeled HER2-directed exosomes exhibit improved cell targeting and specificity, Nanomedical, 16, 553, 10.2217/nnm-2020-0408 · DOI
  116. Agrawal, 2017, Milk-derived exosomes for oral delivery of paclitaxel, Nanomed: Nanotechnol. Biol. Med., 13, 1627, 10.1016/j.nano.2017.03.001 · DOI
  117. Zhang, 2021, CAFs-derived exosomal mirna-130a confers cisplatin resistance of NSCLC cells through pum2-dependent packaging, Int. J. Nanomed., 16, 561, 10.2147/IJN.S271976 · DOI
  118. Ma, 2019, Exosomal transfer of cisplatin-induced miR-425-3p confers cisplatin resistance in NSCLC through activating autophagy, Int. J. Nanomed., 14, 8121, 10.2147/IJN.S221383 · DOI
  119. Zhang, 2021, Exosomes promote the transition of androgen-dependent prostate cancer cells into androgen-independent manner through up-regulating the heme oxygenase-1, Int. J. Nanomed., 16, 315, 10.2147/IJN.S281710 · DOI
  120. Altanerova, 2017, Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia, Int. J. Nanomed., 12, 7923, 10.2147/IJN.S145096 · DOI
  121. Feng, 2019, Exosomal miR-196a-1 promotes gastric cancer cell invasion and metastasis by targeting SFRP1, Nanomedical, 14, 2579, 10.2217/nnm-2019-0053 · DOI
  122. Wang, 2021, A natural membrane vesicle exosome-based sinomenine delivery platform for hepatic carcinoma therapy, Curr. Top. Med. Chem., 21, 1224, 10.2174/1568026621666210612032004 · DOI
  123. Zhang, 2020, Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer, Int. J. Nanomed., 15, 2323, 10.2147/IJN.S231214 · DOI
  124. Fan, 2018, Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer, Theranostics, 8, 5986, 10.7150/thno.26650 · DOI
  125. Ye, 2020, Hsa_circ_0000069 knockdown inhibits tumorigenesis and exosomes with downregulated hsa_circ_0000069 suppress malignant transformation via inhibition of STIL in pancreatic cancer, Int. J. Nanomed., 15, 9859, 10.2147/IJN.S279258 · DOI
  126. Gong, 2019, Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy, J. Nanobiotechnol., 17, 1, 10.1186/s12951-019-0526-7 · DOI
  127. Shojaei, 2021, Delivery of miR-381-3p mimic by mesenchymal stem cell-derived exosomes inhibits triple negative breast cancer aggressiveness; an in vitro study, Stem Cell Rev. Rep., 1
  128. Li, 2020, Hyaluronan decoration of milk exosomes directs tumor-specific delivery of doxorubicin, Carbohydr. Res., 493, 10.1016/j.carres.2020.108032 · DOI
  129. Cohen, 2021, ‘Golden’exosomes as delivery vehicles to target tumors and overcome intratumoral barriers: in vivo tracking in a model for head and neck cancer, Biomater. Sci., 9, 2103, 10.1039/D0BM01735C · DOI
  130. Moradi-Chaleshtori, 2021, Exosome-mediated miR-33 transfer induces M1 polarization in mouse macrophages and exerts antitumor effect in 4T1 breast cancer cell line, Int. Immunopharmacol., 90, 10.1016/j.intimp.2020.107198 · DOI
  131. Donoso-Quezada, 2020, Enhanced exosome-mediated delivery of black bean phytochemicals (Phaseolus vulgaris L.) for cancer treatment applications, Biomed. Pharmacother., 131, 10.1016/j.biopha.2020.110771 · DOI
  132. Xu, 2021, Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment, Biomaterials, 264, 10.1016/j.biomaterials.2020.120369 · DOI
  133. Hosseini, 2021, Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition, DARU J. Pharm. Sci., 29, 267, 10.1007/s40199-021-00400-0 · DOI
  134. Iessi, 2017, Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: a new prototype for theranostics of tumors, J. Enzyme Inhib. Med. Chem., 32, 648, 10.1080/14756366.2017.1292263 · DOI
  135. Bai, 2019, Ultrasound facilitates naturally equipped exosomes derived from macrophages and blood serum for orthotopic glioma treatment, ACS Appl. Mater. Interfaces, 11, 14576, 10.1021/acsami.9b00893 · DOI
  136. Wang, 2021, Downregulation of hsa_circ_0074854 suppresses the migration and invasion in hepatocellular carcinoma via interacting with HuR and via suppressing exosomes-mediated macrophage M2 polarization, Int. J. Nanomed., 16, 2803, 10.2147/IJN.S284560 · DOI
  137. Salunkhe, 2020, Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance, J. Control. Release, 326, 599, 10.1016/j.jconrel.2020.07.042 · DOI
  138. Jung, 2018, Development and MPI tracking of novel hypoxia-targeted theranostic exosomes, Biomaterials, 177, 139, 10.1016/j.biomaterials.2018.05.048 · DOI
  139. Takahashi, 2013, Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection, J. Biotechnol., 165, 77, 10.1016/j.jbiotec.2013.03.013 · DOI
  140. González, 2020, Radioactive labeling of milk-derived exosomes with 99mTc and in vivo tracking by SPECT imaging, Nanomaterials, 10, 1062, 10.3390/nano10061062 · DOI
  141. Chen, 2016, Imaging and intracellular tracking of cancer-derived exosomes using single-molecule localization-based super-resolution microscope, ACS Appl. Mater. Interfaces, 8, 25825, 10.1021/acsami.6b09442 · DOI
  142. Pan, 2020, Passion fruit-like exosome-PMA/Au-BSA@ Ce6 nanovehicles for real-time fluorescence imaging and enhanced targeted photodynamic therapy with deep penetration and superior retention behavior in tumor, Biomaterials, 230, 10.1016/j.biomaterials.2019.119606 · DOI
  143. Betzer, 2017, In vivo neuroimaging of exosomes using gold nanoparticles, ACS Nano, 11, 10883, 10.1021/acsnano.7b04495 · DOI
  144. Wan, 2020, Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium, Theranostics, 10, 218, 10.7150/thno.38198 · DOI
  145. Zhou, 2020, Delivery efficacy differences of intravenous and intraperitoneal injection of exosomes: perspectives from tracking dye labeled and MiRNA encapsulated exosomes, Curr. Drug Deliv., 17, 186, 10.2174/1567201817666200122163251 · DOI
  146. Chen, 2018, Visualization and intracellular dynamic tracking of exosomes and exosomal miRNAs using single molecule localization microscopy, Nanoscale, 10, 5154, 10.1039/C7NR08800K · DOI
  147. Busato, 2017, Labeling and magnetic resonance imaging of exosomes isolated from adipose stem cells, Curr. Protoc. Cell Biol., 75, 3, 10.1002/cpcb.23 · DOI
  148. Liu, 2020, Visualization of exosomes from mesenchymal stem cells in vivo by magnetic resonance imaging, Magn. Reson. Imaging, 68, 75, 10.1016/j.mri.2020.02.001 · DOI
  149. Song, 2020, In situ one-step fluorescence labeling strategy of exosomes via bioorthogonal click chemistry for real-time exosome tracking in vitro and in vivo, Bioconjug. Chem., 31, 1562, 10.1021/acs.bioconjchem.0c00216 · DOI
  150. Santoso, 2020, Exosomes from induced pluripotent stem cell–derived cardiomyocytes promote autophagy for myocardial repair, J. Am. Heart Assoc., 9, 10.1161/JAHA.119.014345 · DOI
  151. Zhuang, 2020, Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p, J. Nanobiotechnol., 18, 1, 10.1186/s12951-020-00716-0 · DOI
  152. Chen, 2021, Intracellular imaging and concurrent pH sensing of cancer-derived exosomes using surface-enhanced Raman scattering, Anal. Bioanal. Chem., 413, 4091, 10.1007/s00216-021-03365-w · DOI
  153. Shao, 2020, Exosomes from long noncoding RNA-Gm37494-ADSCs repair spinal cord injury via shifting microglial M1/M2 polarization, Inflammation, 43, 1536, 10.1007/s10753-020-01230-z · DOI
  154. Deng, 2021, Ultrasound-mediated augmented exosome release from astrocytes alleviates amyloid-β-induced neurotoxicity, Theranostics, 11, 4351, 10.7150/thno.52436 · DOI
  155. Okoye, 2014, MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells, Immunity, 41, 89, 10.1016/j.immuni.2014.05.019 · DOI
  156. Khare, 2018, Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes, Front. Immunol., 9, 3053, 10.3389/fimmu.2018.03053 · DOI
  157. Singla, 2019, Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy, Cells, 8, 1224, 10.3390/cells8101224 · DOI
  158. Riazifar, 2019, Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders, ACS Nano, 13, 6670, 10.1021/acsnano.9b01004 · DOI · Paper page
  159. Cosenza, 2018, Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis, Theranostics, 8, 1399, 10.7150/thno.21072 · DOI
  160. Kang, 2020, Interleukin 35-producing exosomes suppress neuroinflammation and autoimmune uveitis, Front. Immunol., 11, 1051, 10.3389/fimmu.2020.01051 · DOI
  161. Admyre, 2007, B cell–derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines, J. Allergy Clin. Immunol., 120, 1418, 10.1016/j.jaci.2007.06.040 · DOI
  162. Skokos, 2001, Nonspecific B and T cell-stimulatory activity mediated by mast cellsis associated with exosomes, Int. Arch. Allergy Immunol., 124, 133, 10.1159/000053691 · DOI
  163. Bu, 2015, Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis, J. Neuroimmunol., 285, 71, 10.1016/j.jneuroim.2015.04.009 · DOI
  164. Chen, 2006, Efficient induction of antitumor T cell immunity by exosomes derived from heat‐shocked lymphoma cells, Eur. J. Immunol., 36, 1598, 10.1002/eji.200535501 · DOI
  165. Haque, 2021, CD19 chimeric antigen receptor-exosome targets CD19 positive b-lineage acute lymphocytic leukemia and induces cytotoxicity, Cancers, 13, 1401, 10.3390/cancers13061401 · DOI
  166. Li, 2021, Non-small-cell lung cancer regression by sirna delivered through exosomes that display EGFR RNA aptamer, Nucleic Acid Ther.
  167. Jang, 2013, Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors, ACS Nano, 7, 7698, 10.1021/nn402232g · DOI
  168. Zhang, 2018, Genetically engineered liposome‐like nanovesicles as active targeted transport platform, Adv. Mater., 30, 10.1002/adma.201705350 · DOI
  169. Shen, 2020, Marginative delivery-mediated extracellular leakiness and T cell infiltration in lung metastasis by a biomimetic nanoraspberry, Nano Lett., 21, 1375, 10.1021/acs.nanolett.0c04122 · DOI
  170. Xiong, 2019, Pursuing specific chemotherapy of orthotopic breast cancer with lung metastasis from docking nanoparticles driven by bioinspired exosomes, Nano Lett., 19, 3256, 10.1021/acs.nanolett.9b00824 · DOI
  171. Pisano, 2020, Immune (Cell) Derived Exosome Mimetics (IDEM) as a treatment for ovarian cancer, Front. Cell Dev. Biol., 8, 10.3389/fcell.2020.553576 · DOI
  172. Shimbo, 2014, Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration, Biochem. Biophys. Res. Commun., 445, 381, 10.1016/j.bbrc.2014.02.007 · DOI
  173. Jella, 2020, Exosome-containing preparations from postirradiated mouse melanoma cells delay melanoma growth in vivo by a natural killer cell–dependent mechanism, Int. J. Radiat. Oncol. * Biol. * Phys., 108, 104, 10.1016/j.ijrobp.2020.06.016 · DOI
  174. Zhuang, 2020, SPION decorated exosome delivery of TNF-α to cancer cell membranes through magnetism, Nanoscale, 12, 173, 10.1039/C9NR05865F · DOI
  175. Yang, 2016, Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation, J. Cont. Release, 243, 160, 10.1016/j.jconrel.2016.10.008 · DOI
  176. Lu, 2019, Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery, Acta Biomater., 96, 517, 10.1016/j.actbio.2019.07.006 · DOI
  177. Hu, 2020, Exosomes mediated transfer of circ_UBE2D2 enhances the resistance of breast cancer to tamoxifen by binding to miR-200a-3p, Med. Sci. Monit., 6
  178. Qin, 2017, Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner, Int. J. Nanomed., 12, 3721, 10.2147/IJN.S131516 · DOI
  179. Lei, 2018, Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer, Oncol. Rep., 40, 3438
  180. Zheng, 2017, Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells, J. Exp. Clin. Cancer Res., 36, 1, 10.1186/s13046-017-0528-y · DOI
  181. Zhang, 2020, Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma, Mol. Cancer, 19, 1, 10.1186/s12943-020-01222-5 · DOI
  182. Qin, 2019, Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5, Genome Biol., 20, 1, 10.1186/s13059-018-1604-0 · DOI
  183. Dorayappan, 2018, Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins, Oncogene, 37, 3806, 10.1038/s41388-018-0189-0 · DOI
  184. Wang, 2019, Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner, Curr. Drug Metab., 20, 804, 10.2174/1389200220666190819151946 · DOI
  185. Donoso-Quezada, 2020, State-of-the-art exosome loading and functionalization techniques for enhanced therapeutics: a review, Crit. Rev. Biotechnol., 40, 804, 10.1080/07388551.2020.1785385 · DOI
  186. Kanchanapally, 2020, Exosomal formulation escalates cellular uptake of honokiol leading to the enhancement of its antitumor efficacy, ACS Omega, 5, 23299, 10.1021/acsomega.0c03136 · DOI
  187. Aqil, 2017, Exosomes for the enhanced tissue bioavailability and efficacy of curcumin, AAPS J., 19, 1691, 10.1208/s12248-017-0154-9 · DOI
  188. Zhuang, 2011, Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, Mol. Ther., 19, 1769, 10.1038/mt.2011.164 · DOI · Paper page
  189. Tomita, 2020, Macrophage-derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK-3β pathway, Oncol. Rep., 44, 1905
  190. Gao, 2016, Dendritic cell dysfunction and diabetic sensory neuropathy in the cornea, J. Clin. Investig., 126, 1998, 10.1172/JCI85097 · DOI
  191. Bouchareychas, 2020, Macrophage exosomes resolve atherosclerosis by regulating hematopoiesis and inflammation via MicroRNA cargo, Cell Rep., 32, 10.1016/j.celrep.2020.107881 · DOI
  192. Zhang, 2019, MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis, Biomaterials, 200, 35, 10.1016/j.biomaterials.2019.02.006 · DOI
  193. Li, 2019, Macrophage-derived exosomes accelerate wound healing through their anti-inflammation effects in a diabetic rat model, Artif. Cells Nanomed. Biotechnol., 47, 3793, 10.1080/21691401.2019.1669617 · DOI
  194. Wang, 2017, Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury, Mol. Ther., 25, 192, 10.1016/j.ymthe.2016.09.001 · DOI
  195. Li, 2019, Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis, J. Exp. Med., 216, 2562, 10.1084/jem.20190377 · DOI
  196. Nakao, 2021, Exosomes from TNF-α-treated human gingiva-derived MSCs enhance M2 macrophage polarization and inhibit periodontal bone loss, Acta Biomater., 122, 306, 10.1016/j.actbio.2020.12.046 · DOI
  197. Cho, 2018, Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis, Stem Cell Res. Ther., 9, 1, 10.1186/s13287-018-0939-5 · DOI
  198. Liang, 2020, Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer, J. Nanobiotechnol., 18, 10, 10.1186/s12951-019-0563-2 · DOI · Paper page
  199. Xu, 2019, Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization, J. Cell Mol. Med., 23, 7617, 10.1111/jcmm.14635 · DOI
  200. Dai, 2020, Exosomes: key players in cancer and potential therapeutic strategy, Signal Transduct. Target Ther., 5, 145, 10.1038/s41392-020-00261-0 · DOI · Paper page

200 of 201 shown

Cited by

Sorted by citations

Metadata

Authors
Ansari, M. A., Thiruvengadam, M., Venkidasamy, B., Alomary, M. N., Salawi, A., Chung, I.-M., Shariati, M. A., & Rebezov, M.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2022-11
Volume
86
Pages
678-696
ISSN
1044-579X
DOI
10.1016/j.semcancer.2022.04.005
Cited by
63
References
5
Language
en
Licence
Funders
  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning (NRF- 2017R1E1A1A01075282)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review